Dr. Levy on Overcoming Osimertinib Resistance in EGFR-Mutant NSCLC

Video

Benjamin P. Levy, MD, discusses potential strategies to overcome resistance to osimertinib in EGFR-mutant non–small cell lung cancer. 

Benjamin P. Levy, MD, clinical director, Medical Oncology, associate professor of oncology, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, discusses potential strategies to overcome resistance to osimertinib (Tagrisso) in EGFR-mutant non–small cell lung cancer (NSCLC). 

Patients whose tumors harbor EGFR mutations often develop resistance to osimertinib. However, clinical guidelines as to what treatment is optimal for these patients are inconclusive, Levy explains. Data emerged during the 2021 ASCO Annual Meeting showing that the combination of lazertinib (YH25448) and amivantamab-vmjw (Rybrevant) elicited clinically meaningful activity in patients with chemotherapy-naïve, EGFR-mutant NSCLC who had progressed on osimertinib. The regimen has been utilized in other tumor types but offers a potential novel addition to the lung cancer armamentarium. 

Additionally, patritumab deruxtecan (U3-1402), a HER3-directed antibody-drug conjugate (ADCs), demonstrated a confirmed objective response rate of 39% in patients with EGFR-mutant NSCLC who were resistant to EGFR TKIs, Levy says. 

Moreover, the field of lung cancer treatment has evolved beyond using small molecule inhibitors to target novel targets, Levy explains. Oral therapies, bispecific antibodies, and ADCs are being developed for use in offering meaningful outcomes for patients with lung cancer, Levy concludes. 

Related Videos
Tycel Phillips, MD
Ajai Chari, MD
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Jobelle Baldonado, MD
Alexey Danilov, MD, PhD
Hayder Saeed, MD
Joshua K. Sabari, MD, an expert on lung cancer, presenting slides
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington